Background and Purpose-Cerebral microbleeds are frequently seen in the general elderly population, but it is unknown at what rate they occur with aging and whether once present can disappear over time. Methods-As part of the Rotterdam Scan Study, 831 persons (mean age, 68.5 years) underwent repeated brain MRI with a mean interval of 3.4 years. We assessed determinants of incident microbleeds in relation to their location with multiple logistic regressions. Results-Overall prevalence of microbleeds increased from 24.4% at baseline to 28.0% at follow-up. Eighty-five persons (10.2%) developed new microbleeds. Microbleeds at baseline predicted development of new microbleeds (OR, 5.38; 95% CI, 3.34 to 8.67). In only 6 persons with microbleeds at baseline, fewer microbleeds were present at the follow-up examination. Cardiovascular risk factors, presence of lacunar infarcts, and larger white matter lesion volume at baseline were all associated with incident deep or infratentorial microbleeds, whereas people with the apolipoprotein E ⑀4/⑀4 genotype or larger white matter lesion volume had a higher risk of incident strictly lobar microbleeds. Conclusions-Incidence of microbleeds in the general population over a 3-year interval was substantial and microbleeds rarely disappeared. Risk factors for incident microbleeds were similar to those for prevalent microbleeds and differed according to microbleed location. These results support the assessment of microbleeds on T2*-weighted MRI as a possible marker of both cerebral amyloid angiopathy and hypertensive vasculopathy progression. (Stroke. 2011;42:656-661.)
C erebral microbleeds (CMBs) are hypointense lesions seen on T2*-weighted gradient echo MRI that may be indicative of past microhemorrhages. 1 Although their prognosis is yet not completely understood, several clinical studies suggested that CMBs might predict future risk of (recurrent) stroke. 2, 3 Cross-sectional studies have reported on the prevalence and determinants of microbleeds in patients with stroke as well as in the general elderly population. 4 -7 Although numbers varied widely across studies due to differences in MRI technique used, 8 overall, the prevalence of CMBs both in patients with stroke and in the elderly was high and increased with age. Most consistent risk factors were age and hypertension, but markers of cerebral small vessel disease were found to be related as well. 4 -7 In addition, accumulating evidence suggests that the spatial distribution of CMBs may reflect specific underlying vascular pathological changes, in particular cerebral amyloid angiopathy or hypertensive vasculopathy. 8 Progression of these underlying vascular pathological changes may be reflected by development of new CMBs. It is unknown, however, at what rate microbleeds occur with aging in community-dwelling elderly and whether once present can disappear over time. Few longitudinal data on CMBs development exist, and existing studies were all small and performed in specific subgroups such as memory clinic patients or patients with cerebral amyloid angiopathy. 9 -14 To date, there has been no longitudinal study exploring the incidence of microbleeds and its determinants in the general population.
In the population-based Rotterdam Scan Study, we sought to investigate the incidence of CMBs and the location of these new microbleeds. Furthermore, we studied the determinants of incident CMBs in relation to their location. 
Methods Participants

Brain MRI
We performed an identical MRI protocol on the same 1.5-T scanner (GE Healthcare, Milwaukee, WI) at both time points. A 3-dimensional T2*-weighted gradient-recalled echo sequence was used for microbleed detection. 16 The other sequences in the protocol consisted of a T1-weighted sequence, a proton density-weighted sequence, and a fluid-attenuated inversion recovery sequence. 5 No scanner software upgrades or hardware alterations were applied during the study period to ensure comparability of scan data over time.
Rating of CMBs
At both time points, all 3-dimensional T2*-weighted gradientrecalled echo scans were reviewed by 1 of 5 trained raters who recorded the presence, number, and location of microbleeds. All raters were blinded to the other MRI sequences, clinical data, and apolipoprotein E (APOE) genotyping; and the 3-dimensional T2*-weighted gradient-recalled echo scan did not reveal the presence of infarcts or white matter lesions. Microbleeds were defined as focal areas of very low signal intensity. 8 Signal voids caused by sulcal vessels, symmetrical calcifications in the basal ganglia, choroid plexus and pineal calcifications, and signal averaging from bone were excluded. 8 Intraobserver (nϭ500, 1 rater) and interobserver (nϭ300) reliabilities were ϭ0.87 and ϭ0.85, which corresponds to very good agreement. CMBs were categorized into 1 of 3 locations: lobar, deep, or infratentorial. 5 Scans of subjects rated positive for CMBs at at least 1 of 2 time points were included in a side-by-side comparison (M.M.P. and M.W.V.) blinded to the time point of the scans to assess the final number and location of microbleeds in each scan.
Cerebrovascular Disease on MRI
Infarcts were rated on fluid-attenuated inversion recovery, proton density-weighted, and T1-weighted sequences at baseline by the same raters who had scored CMBs according to criteria described previously. 5 White matter lesion volume was quantified with a validated tissue classification technique. 17 
Cardiovascular Risk Factors and APOE Genotyping
Cardiovascular risk factors at baseline were examined by interview and laboratory and physical examination as previously described. 5 APOE genotyping was performed on coded genomic DNA samples. 18 The distributions of APOE genotype and allele frequencies in this population were in Hardy-Weinberg equilibrium.
Data Analysis
We tested differences in baseline characteristics between persons who participated in both examinations and persons who refused or were ineligible to participate in the second MRI using analysis of covariance adjusted for age and sex.
Incidence of CMBs was calculated in 10-year age strata and separately in strata of presence of microbleeds at baseline MRI. Subsequently, we made categories for "strictly lobar incident microbleeds" (persons with Ն1 new microbleeds restricted to a lobar location) and "deep or infratentorial incident microbleeds" (persons with Ն1 new microbleeds in a deep or infratentorial location with or without concomitant lobar microbleeds) 5 and assessed whether the incidence differed according to microbleed location at baseline using multiple logistic regressions.
Next, we assessed the relation of vascular risk factors, APOE allele status, and cerebrovascular disease at baseline to CMB incidence with multiple logistic regressions. These analyses were also performed according to microbleed location.
All regression analyses were adjusted for age, sex, and scan interval. To examine independency of risk factors, we used multivariable modeling, including lacunar infarcts, white matter lesion volume, and vascular risk factors.
Analyses were performed using the statistical package SPSS 15.0 (SPSS Inc, Chicago, IL). Table 1 shows the characteristics of all 1062 participants at baseline. Persons who participated in both MRI examinations were younger compared with persons who participated in the first examination only. Furthermore, participants refusing second MRI were more often APOE ⑀2 carriers, whereas ineligible persons had higher cholesterol, more lacunar infarcts, and a higher white matter lesion volume at baseline, even when differences in age and sex were taken into account.
Results
Mean interval between the 2 MRI assessments was 3.4 years (range, 2.3 to 4.5 years). During this period, overall prevalence of microbleeds increased from 24.4% to 28.0%. Eighty-five of the 831 participants (10.2%) developed new microbleeds on MRI, of whom 38 (4.6%) had multiple new microbleeds (eg, Figure) . CMB incidence increased with age from 7.6% in persons aged 60 to 69 years to 18.6% in participants Ͼ80 years and no significant differences were observed between sexes. Among persons with new microbleeds, 60% had incident strictly lobar CMBs, whereas 40% had incident deep or infratentorial CMBs (Table 2) . Significantly more participants with microbleeds at baseline developed new CMBs during the time interval compared with participants without CMBs at baseline (25.1% versus 5.1%, Table 2 ; OR, 5.38; 95% CI, 3.34 to 8.67; Table 3 ). This risk was even higher for persons with multiple CMBs at baseline (OR, 7.15; 95% CI, 4.11 to 12.44). Moreover, CMB location at baseline strongly predicted the location of new CMBs (Table 3) .
Only in 6 persons (3% of participants with CMBs at baseline) we found less CMBs at follow-up compared with the baseline MRI scan; these persons were added to the group of no incident microbleeds. In 4 of these 6 persons, 1 CMB was scored at baseline, whereas we assessed no CMBs at follow-up; in 1 person CMB count decreased from 2 to 1; in 1 person 11 CMBs were scored on the baseline scan and only 6 at follow-up. Furthermore, there were another 6 participants in whom not all CMBs that were seen at baseline were recognized at the follow-up scan, yet the total number of CMBs did not decrease over time. Except for 1, all of these had Ͼ5 CMBs at baseline and showed an increase in total CMB count at follow-up. In the overall population, we scored 258 new microbleeds, whereas only 18 microbleeds seemed to disappear over time.
Older age, high systolic blood pressure, high pulse pressure, and hypertension at baseline were all associated with development of new microbleeds (Table 4) . When stratified according to location, we found an association of high systolic blood pressure, high pulse pressure, and hypertension with incident deep or infratentorial microbleeds but not with new lobar CMBs. With increasing serum total cholesterol, the incidence of microbleeds in a deep or infratentorial location decreased (Table 4) .
There were no significant differences in microbleed incidence in either location for carriers of either the APOE ⑀2 allele or the APOE ⑀4 allele when compared with persons with the ⑀3/⑀3 genotype (Table 4) . However, when we restricted our analyses to APOE ⑀4/⑀4, we did find an association with development of new microbleeds (OR, 4.43; 95% CI, 1.44 to 13.64). This was especially true for new strictly lobar incident CMBs (OR, 6.60; 95% CI, 1.90 to 22.89), whereas there was no significant association between APOE ⑀4/⑀4 and deep or infratentorial CMBs. Only 5 participants carried the APOE ⑀2/⑀2 genotype; none of them developed new microbleeds during the study period.
Cortical infarcts at baseline were not associated with microbleed incidence (Table 5 ). Lacunar infarcts were strongly related to incident CMBs in participants with new deep or infratentorial microbleeds (OR, 4.46; 95% CI, 1.79 to 11.10), whereas this association in persons with strictly lobar CMBs was less strong and not significant. White matter lesion volume at baseline MRI increased the risk of incident microbleeds in either location (Table 5) .
Additional multivariable modeling to examine independency of risk factors did not change the results (data not shown).
Discussion
Incidence of microbleeds in this population-based study over a 3-year interval was approximately 10% and microbleeds rarely disappeared. Participants with CMBs at baseline had an almost 5-fold increased risk of developing new microbleeds during the follow-up period compared with persons without CMBs at baseline. This was especially true for persons with multiple microbleeds at baseline. Risk factors for incident microbleeds were similar to those for prevalent microbleeds and differed according to microbleed location. Strengths of this study are its population-based setting and its large number of participants with repeated MRI using a 3-dimensional T2*-weighted gradient-recalled echo sequence with proven high sensitivity for microbleed detection. 16 Moreover, we performed an identical MRI protocol on the same 1.5-T scanner at both time points without software or hardware alterations to optimize comparability between scans over time. Another strength is that the raters were blinded to the time point of the scans. This approach prevented overestimation of incident microbleeds and allowed us to assess potential vanishing of CMBs over time.
A possible limitation of the study is that selective dropout may have influenced our results. People who participated were younger and healthier compared with those who refused a second MRI scan or, in particular, were ineligible. If at all, this may have led us to underestimate the true incidence of microbleeds in the population at large. Due to this selection, associations between risk factors and CMB incidence may also have been underestimated. However, when we repeated the cross-sectional analyses we previously reported on at baseline 5 in the 831 persons with a second MRI assessment, we found similar associations (data not shown), indicating limited selection bias.
In the previously mentioned cross-sectional analyses, 5 we found an association between cardiovascular risk factors, presence of lacunar infarcts, and white matter lesions and prevalent microbleeds in a deep or infratentorial region but not in a lobar location. Moreover, APOE ⑀4 carriers had significantly more often strictly lobar CMBs than noncarriers. In our current study, we observed similar associations between these risk factors and development of new CMBs in the specified locations, indicating that microbleed incidence, in line with microbleed prevalence, may result from different underlying vascular pathology, that is, cerebral amyloid angiopathy and hypertensive vasculopathy.
Few studies in selected subgroups, mainly among patients with stroke and patients with cerebral amyloid angiopathy, have reported on CMB incidence. 9 -14 These studies report a wide range of incidence rates (12% to 50%), which may largely be explained by differences in study populations, scan interval time, and MRI protocols. Of note is that the use of an optimized high-resolution sequence like in our study likely results in a higher incidence of microbleeds compared with less sensitive sequences. 16 Overall, studies have consistently shown that microbleeds at baseline predict development of new microbleeds. 9 -13 Moreover, vascular risk factors have been associated with incident CMBs in previous studies. 9, 10 However, only 1 study made separate categories according to CMB location and they did not find a relation of vascular risk factors and incidence of deep or infratentorial CMBs. 9 In our study, the association between vascular risk factors and incident deep or infratentorial microbleeds remained significant after adjustment for other markers of small vessel disease. This suggests that deep or infratentorial microbleeds are an independent indicator of hypertensive vasculopathy. Previous studies in memory clinic patients and patients with cerebral amyloid angiopathy found an association between APOE ⑀4 or ⑀2 carriership and incident CMBs. 9,13 Although we could not reproduce this in the general population, we did find that the APOE ⑀4/⑀4 genotype was related to incident CMBs, in particular incident strictly lobar microbleeds. An explanation for the lack of an association with APOE ⑀4 allele in our study compared with others may be the higher prevalence of both determinant and outcome in previous clinical studies compared with our community-dwelling elderly population. In contrast to the baseline cross-sectional study, 5 we now also found an association between white matter lesion volume at baseline and incidence of strictly lobar microbleeds, which is in line with other studies. 9, 11 It may be hypothesized that vascular amyloid deposition alters white matter perfusion and thus causes white matter lesions through vessel stenosis, vasoactive effects of ␤-amyloid, and smooth muscle cell necrosis that results in loss of vasoreactivity. 19, 20 In our study, in 12 persons (1.4% of overall study population; 5.9% of persons with CMBs at baseline), some CMBs that were present at baseline seemed to disappear over time. In only 6 of these, this led to a decrease in overall microbleed count at the follow-up examination. This low percentage is comparable with other studies that also found a very small percentage of microbleeds to disappear over time. 9, 10, 12 In contrast, some studies suggested that there may be more widespread dynamism and resolution of CMBs, but these studies were based on very few cases. 21 Furthermore, lower quality of imaging will not only influence the incidence rate of microbleeds, but will also result in microbleeds not being detected on either baseline or follow-up MRI scan, which may falsely suggest resolution of microbleeds. 8 We cannot, however, rule out the possibility that some CMBs both occurred and disappeared in the time interval between both scans, although this number is likely low based on our available data.
Conclusions
Our results support the assessment of microbleeds on T2*-weighted MRI as a possible marker of both cerebral amyloid angiopathy and hypertensive vasculopathy progression. Strict control of vascular risk factors, especially in persons who already have microbleeds, may potentially slow down progression of pathology and may perhaps prevent symptomatic intracerebral hemorrhage in the long run. Further studies are warranted to investigate this hypothesis.
